-

Kyverna Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX).

According to a securities lawsuit filed against the Company, the registration statement and prospectus Kyverna used to conduct its initial public offering on February 8, 2024 (the “IPO”) misstated and/or omitted material facts about the results of the Company’s ongoing clinical evaluation of KYV-101, its lead product candidate. Specifically, the lawsuit alleges that Kyverna touted patient “improvement” in certain indicators while failing to disclose adverse data from one of its clinical trials, even though that data was known to the Company at the time of the IPO. As a result, investors allegedly purchased Kyverna shares at artificially inflated prices. When the true details entered the market, the lawsuit claims, investors suffered damages.

KSF’s investigation is focusing on whether Kyverna’s officers and/or directors of breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Kyverna’s shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-kytx/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-833-538-3606
1100 Poydras St., Suite 960
New Orleans, LA 70163

Kahn Swick & Foti, LLC

NASDAQ:KYTX

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-833-538-3606
1100 Poydras St., Suite 960
New Orleans, LA 70163

Social Media Profiles
More News From Kahn Swick & Foti, LLC

Charter Communications Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charter Communications, Inc. - CHTR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Charter Communications, Inc. (NasdaqGS: CHTR). In December 2021, Charter began participating in the FCC’s Affordable Connectivity Program (“ACP”), receiving federal subsidies to offer low-income households discounted internet service. In June 2024, the ACP ended after its federal fu...

QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NasdaqGS: QDEL). According to a securities class action filed against the Company, internal reports and accounts from former employees described serious and unresolved problems with the Company’s flagship test, the Savanna Re...

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are...
Back to Newsroom